NasdaqCM - Delayed Quote USD

Liquidia Corporation (LQDA)

18.88
-0.42
(-2.18%)
At close: May 16 at 4:00:02 PM EDT
18.31
-0.57
(-3.02%)
After hours: May 16 at 7:45:13 PM EDT
Loading Chart for LQDA
  • Previous Close 19.30
  • Open 19.30
  • Bid 13.74 x 200
  • Ask 24.19 x 200
  • Day's Range 18.67 - 19.41
  • 52 Week Range 8.26 - 19.41
  • Volume 1,075,750
  • Avg. Volume 1,165,879
  • Market Cap (intraday) 1.614B
  • Beta (5Y Monthly) 0.24
  • PE Ratio (TTM) --
  • EPS (TTM) -1.71
  • Earnings Date Aug 5, 2025 - Aug 11, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 27.22

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

www.liquidia.com

170

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LQDA

View More

Performance Overview: LQDA

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LQDA
60.54%
S&P 500 (^GSPC)
1.30%

1-Year Return

LQDA
48.19%
S&P 500 (^GSPC)
12.48%

3-Year Return

LQDA
232.98%
S&P 500 (^GSPC)
48.66%

5-Year Return

LQDA
156.17%
S&P 500 (^GSPC)
108.07%

Compare To: LQDA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LQDA

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    1.61B

  • Enterprise Value

    1.59B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    108.33

  • Price/Book (mrq)

    32.47

  • Enterprise Value/Revenue

    112.55

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -37.66%

  • Return on Equity (ttm)

    -203.98%

  • Revenue (ttm)

    14.14M

  • Net Income Avi to Common (ttm)

    -138.68M

  • Diluted EPS (ttm)

    -1.71

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    169.76M

  • Total Debt/Equity (mrq)

    297.04%

  • Levered Free Cash Flow (ttm)

    -64.38M

Research Analysis: LQDA

View More

Company Insights: LQDA

Research Reports: LQDA

View More

People Also Watch